Gastroenterology & Hepatology Clinical Trials

Statistical methods in gastroenterology & hepatology trials

The methods these trials rely on most, based on the statistical analyses posted to ClinicalTrials.gov, with the tutorial that explains each one.

All gastroenterology & hepatology trials

642 results

• NAFLDIndependent statistical analysis of Endoscopic Ultrasound(EUS)-Guided TRUCUT Biopsy (EUS-TCB) of Suspected Nonalcoholic Fatty Liver Disease(NAFLD.): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase NAResults postedn = 21NCT00586313
• NAFLDIndependent statistical analysis of Magnetic Resonance Spectroscopy (MRS) Validation Study in Individuals With Nonalcoholic Fatty Liver Disease (NAFLD): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase NAResults postedn = 14NCT00940537
• NASH-CXIndependent statistical analysis of Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis: primary endpoint results,…Phase 2Results postedn = 162NCT02462967
• NavigatorIndependent statistical analysis of A Study to Evaluate Paritaprevir With Ritonavir (ABT-450/r) When Given Together With Ombitasvir and With and Without Ribavirin (RBV) in Treatment-Naïve Participants With Genotype 1, 2 or 3…Phase 2Results postedn = 61NCT01458535
• Neoadjuvant Accelerated Short Course Radiation Therapy With Photons and Capecitabine for Resectable Pancreatic Cancer: Complete Statistical AnalysisIndependent statistical analysis of Neoadjuvant Accelerated Short Course Radiation Therapy With Photons and Capecitabine for Resectable Pancreatic Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 1/2Results postedn = 10NCT00889187
• NEST-1Independent statistical analysis of Combination Immunotherapy in Colorectal Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05571293).Phase 2Results postedn = 26NCT05571293
• Nintedanib (BIBF 1120) vs Placebo in Refractory Metastatic Colorectal Cancer (LUME-Colon 1): Complete Statistical AnalysisIndependent statistical analysis of Nintedanib (BIBF 1120) vs Placebo in Refractory Metastatic Colorectal Cancer (LUME-Colon 1): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 3Results postedn = 768NCT02149108
• Ninvasive Cardiac Output Measurements During Cesarean Delivery Under Spinal Anesthesia.: Complete Statistical AnalysisIndependent statistical analysis of Ninvasive Cardiac Output Measurements During Cesarean Delivery Under Spinal Anesthesia.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01928797).Phase NAResults postedn = 60NCT01928797
• Niraparib + Dostarlimab + RT in Pancreatic Cancer: Complete Statistical AnalysisIndependent statistical analysis of Niraparib + Dostarlimab + RT in Pancreatic Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04409002).Phase 2Results postedn = 18NCT04409002
• Nivolumab and Ipilimumab in Mucinous Colorectal and Appendiceal Tumors: Complete Statistical AnalysisIndependent statistical analysis of Nivolumab and Ipilimumab in Mucinous Colorectal and Appendiceal Tumors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03693846).Phase 2Results postedn = 11NCT03693846
• NKTR-102 in Combination With Cetuximab in Patients With Refractory Solid Tumors (Phase 2a) and Metastatic or Locally Advanced Colorectal Cancer (Phase 2b): Complete Statistical AnalysisIndependent statistical analysis of NKTR-102 in Combination With Cetuximab in Patients With Refractory Solid Tumors (Phase 2a) and Metastatic or Locally Advanced Colorectal Cancer (Phase 2b): primary endpoint results, effect estimate with…Phase 2Results postedn = 18NCT00598975
• NOCTIndependent statistical analysis of Multicenter Randomized Parallel Group Phase III Study Comparing the Bowel Cleansing Efficacy, Safety and Tolerability of NER1006 Versus Trisulfate Solution Using 2-Day Split-Dosing Regimen in Adults: primary endpoint…Phase 3Results postedn = 621NCT02254486
• Non Invasive Ventilation as Airway Clearance in Patients With Cystic Fibrosis: Complete Statistical AnalysisIndependent statistical analysis of Non Invasive Ventilation as Airway Clearance in Patients With Cystic Fibrosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase NAResults postedn = 32NCT02083263
• Non-DrinkerIndependent statistical analysis of Acetaminophen Adduct Formation in Non-Drinkers Taking Therapeutic Doses of Acetaminophen for Ten Consecutive Days: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 4Results postedn = 35NCT00616018
• NOTABLeIndependent statistical analysis of Neuromodulation for Accidental Bowel Leakage: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03278613).Phase NAResults postedn = 166NCT03278613
• Novel Management of Airway Protection in Parkinson’s Disease: A Clinical Trial: Complete Statistical AnalysisIndependent statistical analysis of Novel Management of Airway Protection in Parkinson's Disease: A Clinical Trial: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 2Results postedn = 65NCT02927691
• Novel Pharyngeal Metrics to Predict Dysphagia Outcomes: Complete Statistical AnalysisIndependent statistical analysis of Novel Pharyngeal Metrics to Predict Dysphagia Outcomes: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04569097).Phase NAResults postedn = 227NCT04569097
• NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours: Complete Statistical AnalysisIndependent statistical analysis of NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 1/2Results postedn = 19NCT05714553
• Obesity and Nonalcoholic Fatty Liver Disease: Complete Statistical AnalysisIndependent statistical analysis of Obesity and Nonalcoholic Fatty Liver Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00262964).Phase NAResults postedn = 51NCT00262964
• OCT Pilot in Esophagus: Complete Statistical AnalysisIndependent statistical analysis of OCT Pilot in Esophagus: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03434834).Phase NAResults postedn = 53NCT03434834
• One Year Study of Rifaximin Delayed Release (DR) in Crohn’s Disease: Complete Statistical AnalysisIndependent statistical analysis of One Year Study of Rifaximin Delayed Release (DR) in Crohn's Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 3Results postedn = 81NCT02240108
• OPALINEIndependent statistical analysis of OPALINE : A Study Of Morbidity And Mortality At 2 Years: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase NAResults postedn = 144NCT02264665
• Open Label Safety Study of Enteric-Coated Spheroid Suspension in Infants Aged Less Than 12 Months With Presumed Gastroesophageal Reflux Disease (GERD): Complete Statistical AnalysisIndependent statistical analysis of Open Label Safety Study of Enteric-Coated Spheroid Suspension in Infants Aged Less Than 12 Months With Presumed Gastroesophageal Reflux Disease (GERD): primary endpoint results, effect estimate with confidence…Phase 3Results postedn = 58NCT00868296
• Open-Label Study of AB-729, Nucleos(t)Ide Analogue and Pegylated Interferon Alfa-2a in Subjects With Chronic Hepatitis B Infection: Complete Statistical AnalysisIndependent statistical analysis of Open-Label Study of AB-729, Nucleos(t)Ide Analogue and Pegylated Interferon Alfa-2a in Subjects With Chronic Hepatitis B Infection: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase 2Results postedn = 43NCT04980482
• OPERA IIIndependent statistical analysis of OPERA II, a phase 2 single-group study of long-term treatment with PF-00547659 in Crohn's Disease, including its design, adverse-event endpoint, statistical interpretation, and limitations.Phase 2Results postedn = 268NCT01298492
• OPERA IIIndependent statistical analysis of A Study To Monitor Long-Term Treatment With PF-00547659: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01298492).Phase 2Results postedn = 268NCT01298492
• Operative vs Non-Operative Management of Acute Appendicitis and Acute Cholecystitis in COVID-19 Positive Patients: Complete Statistical AnalysisIndependent statistical analysis of Operative vs Non-Operative Management of Acute Appendicitis and Acute Cholecystitis in COVID-19 Positive Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase NAResults postedn = 2NCT04748120
• Optical Frequency Domain Imaging (OFDI) Surveillance and Image Guided Biopsy of the Esophagus: Complete Statistical AnalysisIndependent statistical analysis of Optical Frequency Domain Imaging (OFDI) Surveillance and Image Guided Biopsy of the Esophagus: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase NAResults postedn = 22NCT01439633
• Optimal Care of Complicated Appendicitis: Complete Statistical AnalysisIndependent statistical analysis of Optimal Care of Complicated Appendicitis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03159754).Phase 4Results postedn = 40NCT03159754
• OPTISCREEN-BIndependent statistical analysis of Application of HBV Rapid Tests as a Tool for Wide-Use Screening: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase NAResults postedn = 1,000NCT01767597
• Oral Etrasimod Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis in Adult Japanese Participants (ELEVATE UC 40 JAPAN): Complete Statistical AnalysisIndependent statistical analysis of Oral Etrasimod Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis in Adult Japanese Participants (ELEVATE UC 40 JAPAN): primary endpoint results, effect estimate with…Phase 3Results postedn = 42NCT04706793
• Oral OKT3 for the Treatment of Active Ulcerative Colitis: Complete Statistical AnalysisIndependent statistical analysis of Oral OKT3 for the Treatment of Active Ulcerative Colitis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01287195).Phase 1/2Results postedn = 6NCT01287195
• Oral Zinc for the Treatment of Acute Diarrhea in US Children: Complete Statistical AnalysisIndependent statistical analysis of Oral Zinc for the Treatment of Acute Diarrhea in US Children: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase NAResults postedn = 71NCT01198587
• ORANGEIndependent statistical analysis of Oral Amino Acid Nutrition to Improve Glucose Excursions in PCOS: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03717935).Phase NAResults postedn = 27NCT03717935
• Oslo-CoMetIndependent statistical analysis of Oslo Randomized Laparoscopic Versus Open Liver Resection for Colorectal Metastases Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase NAResults postedn = 280NCT01516710
• Oxaliplatin Microdosing Assay in Predicting Exposure and Sensitivity to Oxaliplatin-Based Chemotherapy: Complete Statistical AnalysisIndependent statistical analysis of Oxaliplatin Microdosing Assay in Predicting Exposure and Sensitivity to Oxaliplatin-Based Chemotherapy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase NAResults postedn = 6NCT02569723
• Paclitaxel, Pembrolizumab and Olaparib in Previously Treated Advanced Gastric Adenocarcinoma: Complete Statistical AnalysisIndependent statistical analysis of Paclitaxel, Pembrolizumab and Olaparib in Previously Treated Advanced Gastric Adenocarcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04209686).Phase 2Results postedn = 19NCT04209686
• PADD-ONIndependent statistical analysis of Peg-interferon ADDed to an Ongoing Nucleos(t)Ide Based Treatment in Patients With Chronic Hepatitis B to Induce Decrease of HBs-Antigen: primary endpoint results, effect estimate with confidence interval, sample-size…Phase 2Results postedn = 170NCT01524679
• PANCAX-3Independent statistical analysis of Pancreaze (Pancrelipase) for Patients With Pancreatic Adenocarcinoma With Cachexia and Exocrine Pancreatic Insufficiency: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 2Results postedn = 36NCT04098237
• PANTHERIndependent statistical analysis of Efficacy of Pantoprazole in Patients Older Than 12 Years Who Have Symptoms of Non-Erosive Reflux Disease (NERD) or Erosive Gastroesophageal Reflux Disease (eGERD): primary endpoint results, effect estimate…Phase NAResults postedn = 1,995NCT00561730
• PANVAC-V and PANVAC-F Vaccines Plus Sargramostim to Treat Advanced Cancer: Complete Statistical AnalysisIndependent statistical analysis of PANVAC-V and PANVAC-F Vaccines Plus Sargramostim to Treat Advanced Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00088413).Phase 1/2Results postedn = 51NCT00088413
• Patient Acceptance and Preference Among Screening Modalities for Detection of Barrett’s Esophagus: Complete Statistical AnalysisIndependent statistical analysis of Patient Acceptance and Preference Among Screening Modalities for Detection of Barrett's Esophagus: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase NAResults postedn = 24NCT04301986
• PEAK: Panitumumab Plus mFOLFOX6 vs. Bevacizumab Plus mFOLFOX6 for First Line Treatment of Metastatic Colorectal Cancer (mCRC) Patients With Wild-Type Kirsten Rat Sarcoma-2 Virus (KRAS) Tumors: Complete Statistical AnalysisIndependent statistical analysis of PEAK: Panitumumab Plus mFOLFOX6 vs. Bevacizumab Plus mFOLFOX6 for First Line Treatment of Metastatic Colorectal Cancer (mCRC) Patients With Wild-Type Kirsten Rat Sarcoma-2 Virus (KRAS) Tumors: primary endpoint…Phase 2Results postedn = 285NCT00819780
• PEARL-IIndependent statistical analysis of A Study to Evaluate the Safety and Effect of Co-administration of ABT-450 With Ritonavir (ABT-450/r) and ABT-267 in Adults With Chronic Hepatitis C Virus Infection: primary endpoint results,…Phase 2Results postedn = 316NCT01685203
• PEARL-IVIndependent statistical analysis of A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1a Infection: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 3Results postedn = 305NCT01833533
• Pediatric Liver Fat Quantification (LFQ) Phase 2 Pilot Study: Complete Statistical AnalysisIndependent statistical analysis of Pediatric Liver Fat Quantification (LFQ) Phase 2 Pilot Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04800094).Phase NAResults postedn = 30NCT04800094
• Peer Mentorship: An Intervention To Promote Effective Pain Self-Management In Adolescents: Complete Statistical AnalysisIndependent statistical analysis of Peer Mentorship: An Intervention To Promote Effective Pain Self-Management In Adolescents: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase NAResults postedn = 27NCT01118988
• PeerPrEPIndependent statistical analysis of Peer PrEP Referral + HIV Self-test Delivery for PrEP Initiation in Kenya: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase NAResults postedn = 211NCT04982250
• Peg-Intron/Ribavirin in G 1 HCV for Non-Extended Versus 24 Week Extended Treatment After 24 Weeks (Study P04144)(COMPLETED): Complete Statistical AnalysisIndependent statistical analysis of Peg-Intron/Ribavirin in G 1 HCV for Non-Extended Versus 24 Week Extended Treatment After 24 Weeks (Study P04144)(COMPLETED): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase 4Results postedn = 160NCT00202839
• PEGHOPEIndependent statistical analysis of An Observational Study of Pegasys (Peginterferon Alfa-2a) Plus Copegus (Ribavirin) in Participants With Chronic Hepatitis C (CHC), Genotype 2, 3, 1 or 4, Undergoing Opioid Maintenance Therapy: primary…Phase NAResults postedn = 88NCT01416610

← All therapeutic areas